Using a Blood Biomarker to Distinguish Benign From Malignant Pulmonary Nodules: A Subgroup Analysis Comparing Screen Detection, Sex, Smoking History, and Nodule Size.

Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: J. S. K. discloses consulting/advisory (Ambu, Biodesix, Inc., Boston Scientific, Cook, Intuitive, Level Ex, Medtronic, Pinnacle Biologics, Pulmonx), research funding (Lung Therapeutics, PrognomiQ), honoraria (Pinnacle Biologics), speaker’s bureau (Biodesix, Inc., Veracyte), stock ownership (Doximity), and travel/accommodations/expenses (Auris); M. A. P. discloses honoraria (Medtronic, Philips, Astra Zeneca), consulting (Medtronic, Philips, Intuitive, Johnson & Johnson, Pfizer, Noah Medical, Galvanize Therapeutics, PreView Medical), research funding (Intuitive, Medtronic, Philips, Biodesix, Inc.), speaker’s bureau (Johnson & Johnson, United Therapeutics, Biodesix, Inc.), and travel/accommodations/expenses (Intuitive, Johnson & Johnson, Astra Zeneca, Pfizer, Noah Medical); T. P. discloses employment (Biodesix, Inc.); G. A. S. discloses research funding (Biodesix, Inc.) and consulting (Biodesix, Inc.). None declared (K. J. L.).